Joshua S. Prince, MBA

Joshua S. Prince, MBA

Chief Operating OfficeratVistagen Therapeutics· In proxies 2023–2025

Pay in FY2025+86% from the year before · Vistagen Therapeutics stock -52.7% the same year

Joshua S. Prince, MBA was paid $1.1M in FY2025 (Mar), up 86%. Vistagen Therapeutics stock fell 52.7% that year.

Pay$100 in the stock at the end of FY22 → $7
Pay is from the Summary Compensation Table of each Vistagen Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Vistagen TherapeuticsPublic company · 3 yr
    • Chief Operating Officer2023 – Present · 3 yrStock in role -100%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?